• Compass Pathways’ third-quarter 2026 net loss narrowed 93% year over year to $9.83 million, primarily due to noncash warrant fair-value adjustments.
• Selling, general and administrative expenses more than doubled year over year to $32.98 million, primarily due to commercial launch preparations.
• Cash and cash equivalents totaled $444 million at September 30, expected to fund operations and capital expenditure into 2028.
• The final COMP360 new drug application submission is expected within two weeks, with rolling review underway.
• Launch preparations remain on track for the first half of 2027, subject to FDA approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202611030630BIZWIRE_USPR_____20261103_BW539380) on November 03, 2026, and is solely responsible for the information contained therein.